EUVIMEDEUVIMED entdecken
Crossref

The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir

Toshihisa Nakashima iD, Azusa Kawasaki, Yoshihiro Inamoto, Ayumu Ito, Takahiro Fukuda, Hironobu Hashimoto

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Toshihisa Nakashima und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Tacrolimus, Hematopoietic Stem Cell Transplantation, Triazoles, Immunosuppressive Agents. Die Arbeit nennt 15 Literaturangaben. Gefördert von: National Cancer Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Letermovir, a moderate inhibitor of CYP3A4 and inducer of CYP2C9 and CYP2C19, is used for cytomegalovirus prophylaxis following allogeneic hematopoietic stem cell transplantation (HCT). Posaconazole also inhibits CYP3A4, affecting tacrolimus metabolism. This study aimed to examine tacrolimus conversion ratios when switching from continuous intravenous to oral administration in HCT patients receiving posaconazole with and without letermovir. Tacrolimus concentration-to-dose (C/D) ratios before (C/Dciv) and after (C/Dpo) conversion were compared. The median C/Dciv ratios were 20.1 and 22.5 (ng/mL)/(mg/day) for patients with and without letermovir, respectively (P = 0.31). The median C/Dpo ratios were 5.1 and 5.9 (ng/mL)/(mg/day), respectively (P = 0.43). The median (C/Dpo)/(C/Dciv) ratios were 0.25 and 0.24, respectively (P = 0.77), indicating no significant difference in tacrolimus conversion ratios with and without letermovir. Based on these findings, the tacrolimus conversion ratio in patients receiving posaconazole was estimated to be approximately 1:2, regardless of concomitant letermovir use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusHematopoietic Stem Cell TransplantationTriazolesImmunosuppressive AgentsAcetatesQuinazolinesHumansMaleFemaleMiddle AgedAdministration, OralAdultAgedCytomegalovirus InfectionsAntiviral AgentsAdministration, IntravenousRetrospective StudiesYoung Adult

Stichwörter der Autor:innen

allogeneic hematopoietic cell transplantationdrug–drug interactionletermovirposaconazoletacrolimus

Substanzen

TacrolimusposaconazoleletermovirTriazolesImmunosuppressive AgentsAcetatesQuinazolinesAntiviral Agents

Autor:innen und Institutionen

  • Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Toshihisa Nakashima

Förderung

  • National Cancer Research and Development Fund

Zitieren

APA

Nakashima, T., Kawasaki, A., Inamoto, Y., Ito, A., Fukuda, T., & Hashimoto, H. (2025). The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf101

Vancouver

Nakashima T, Kawasaki A, Inamoto Y, Ito A, Fukuda T, Hashimoto H. The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf101

BibTeX
@article{Nakashima2025,
  author = {Nakashima, Toshihisa and Kawasaki, Azusa and Inamoto, Yoshihiro and Ito, Ayumu and Fukuda, Takahiro and Hashimoto, Hironobu},
  title = {The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf101}
}
Kostenlos starten →